Berapa harga Becton, Dickinson and Company (BDX)

Harga Becton, Dickinson and Company (BDX) adalah $183.43

Apa kapitalisasi pasar Becton, Dickinson and Company (BDX)

Kapitalisasi pasar Becton, Dickinson and Company (BDX) adalah $50.54B

Riwayat Harga Becton, Dickinson and Company (BDX)

Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.

Tahun	Performa
2026 (TTM)	3.49%
2025	-13.14%
2024	-5.83%
2023	-5.05%
2022	3.30%
2021	2.09%
2020	-8.09%
2019	16.06%
2018	4.62%
2017	31.63%
2016	7.93%
2015	10.88%
2014	28.58%
2013	38.50%
2012	6.62%
2011	-11.96%
2010	7.01%
2009	18.57%
2008	-20.96%
2007	15.40%
2006	21.52%
2005	4.22%
2004	40.72%
2003	31.83%
2002	-7.69%
2001	0.00%

Tahun

Performa

2026 (TTM)

3.49%

2025

-13.14%

2024

-5.83%

2023

-5.05%

2022

3.30%

2021

2.09%

2020

-8.09%

2019

16.06%

2018

4.62%

2017

31.63%

2016

7.93%

2015

10.88%

2014

28.58%

2013

38.50%

2012

6.62%

2011

-11.96%

2010

7.01%

2009

18.57%

2008

-20.96%

2007

15.40%

2006

21.52%

2005

4.22%

2004

40.72%

2003

31.83%

2002

-7.69%

2001

0.00%

Perusahaan	Harga saham	Perubahan 1th%	Negara
Intuitive Surgical, Inc. ISRG.US	$404.94	-7.57%	US
EssilorLuxottica S.A. EL.PA	$170.51	-45.06%	FR
HOYA Corporation 7741.T	$153.75	11.49%	JP
Alcon Inc. ALC.SW	$69.48	-5.58%	CH
Medline Inc. MDLN.US	$34.85	-	US

Perusahaan

Harga saham

Perubahan 1th%

Negara